[1]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin., 2020, 70(1), 7-34.
[2]
M.C., Hulvat Cancer incidence and trends. Surg. Clin. N. Am., 2020, 100(3), 469-481.
[3]
Singh, T.P.; Singh, O.M. Recent progress in biological activities of indole and indole alkaloids. Anticancer. Agents Med. Chem., 2018, 18(1), 9-25.
[4]
Zhu, H.L.; Lv, P.C.; Zhu, H.L. Indole-based, antiproliferative agents targeting tubulin polymerization. Curr. Top. Med. Chem., 2017, 17(2), 120-137.
[5]
Gomstyan, A. Heterocycles in drugs and drug discovery. Chem. Heterocycl. Compd., 2012, 48, 7-10.
[6]
Kaur, R.; Palta, K.; Kumar, M.; Bhargava, M.; Dahiya, L. Therapeutic potential of oxazole scaffold: A patent review (2006-2017). Expert Opin. Ther. Pat., 2018, 28(11), 783-812.
[7]
Zhou, H.; Cheng, J.Q.; Wang, Z.S.; Chen, F.H.; Liu, X.H. Oxazole: A promising building block for the development of potent antitumor agents. Curr. Top. Med. Chem., 2016, 16(30), 3582-3589.
[8]
Yadav, V.; Talwar, P. Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: An underestimated truth. Biomed. Pharmacother., 2019, 111, 934-946.
[9]
Shi, Z.Y.; Li, Y.Q.; Kang, Y.H.; Hu, G.Q.; Huang, C.S.; Deng, J.B.; Liu, B. Piperonal ciprofloxacin hydrazone induces growth arrest and apoptosis of human hepatocarcinoma SMMC-7721 cells. Acta Pharmacol. Sin., 2012, 33, 271-278.
[10]
Xu, Q.J.; Hou, L.L.; Wu, X.K.; Xie, S.Q.; Hu, G.Q.; Huang, W.L. Synthesis and antitumor activity of ciprofloxacin bis-(C3/C7 hydrozone)s. J. Chin. Pharmaceut. Univer., 2013, 44 , 35-38
